Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection
Identifieur interne : 000731 ( Main/Exploration ); précédent : 000730; suivant : 000732Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection
Auteurs : Noriyuki Yamamoto [Japon] ; Yasuhiko Izumi [Japon] ; Takaaki Matsuo [Japon] ; Seiko Wakita [Japon] ; Toshiaki Kume [Japon] ; Yuki Takada-Takatori [Japon] ; Hideyuki Sawada [Japon] ; Akinori Akaike [Japon]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2010-07.
English descriptors
Abstract
Postmortem studies have shown that heme oxygenase‐1 (HO‐1) immunoreactivity is increased in patients with Parkinson disease. HO‐1 expression is highly upregulated by a variety of stress. Since the proteasome activity is decreased in patients with Parkinson disease, we investigated whether proteasome activity regulates HO‐1 content. MG‐132, a proteasome inhibitor, increased the amount of HO‐1 protein mainly in astrocytes of primary mesencephalic cultures. Quantitative RT‐PCR analysis revealed that lactacystin upregulated HO‐1 mRNA expression. Proteasome inhibition with MG132 also increased the cytomegalovirus promoter‐driven expression of Flag‐HO‐1 protein and resulted in an accumulation of ubiquitinated Flag‐HO‐1 in Flag‐HO‐1‐overexpressing PC12 cells. In addition, a cycloheximide chase assay demonstrated that the degradation of Flag‐HO‐1 protein was slowed by MG‐132. Next, the function of HO‐1 which was upregulated by proteasome inhibitors was examined. Proteasome inhibitors protected dopaminergic neurons from 6‐hydroxydopamine (6‐OHDA)‐induced toxicity and this neuroprotection was abrogated by co‐treatment with zinc protoporphyrin IX, a HO‐1 inhibitor. Furthermore, 6‐OHDA‐induced toxicity was blocked by bilirubin and carbon monoxide, products of the HO‐1‐catalyzed degradation of heme. These results suggest that mesencephalic HO‐1 protein level is regulated by proteasome activity and the elevation by proteasome inhibition affords neuroprotection. © 2010 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.22363
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection</title><author><name sortKey="Yamamoto, Noriyuki" sort="Yamamoto, Noriyuki" uniqKey="Yamamoto N" first="Noriyuki" last="Yamamoto">Noriyuki Yamamoto</name></author><author><name sortKey="Izumi, Yasuhiko" sort="Izumi, Yasuhiko" uniqKey="Izumi Y" first="Yasuhiko" last="Izumi">Yasuhiko Izumi</name></author><author><name sortKey="Matsuo, Takaaki" sort="Matsuo, Takaaki" uniqKey="Matsuo T" first="Takaaki" last="Matsuo">Takaaki Matsuo</name></author><author><name sortKey="Wakita, Seiko" sort="Wakita, Seiko" uniqKey="Wakita S" first="Seiko" last="Wakita">Seiko Wakita</name></author><author><name sortKey="Kume, Toshiaki" sort="Kume, Toshiaki" uniqKey="Kume T" first="Toshiaki" last="Kume">Toshiaki Kume</name></author><author><name sortKey="Takada Akatori, Yuki" sort="Takada Akatori, Yuki" uniqKey="Takada Akatori Y" first="Yuki" last="Takada-Takatori">Yuki Takada-Takatori</name></author><author><name sortKey="Sawada, Hideyuki" sort="Sawada, Hideyuki" uniqKey="Sawada H" first="Hideyuki" last="Sawada">Hideyuki Sawada</name></author><author><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:838363552C12D01E9EC63C11DAEDE8EB5364C25F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/jnr.22363</idno><idno type="url">https://api.istex.fr/document/838363552C12D01E9EC63C11DAEDE8EB5364C25F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002388</idno><idno type="wicri:Area/Main/Curation">002063</idno><idno type="wicri:Area/Main/Exploration">000731</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection</title><author><name sortKey="Yamamoto, Noriyuki" sort="Yamamoto, Noriyuki" uniqKey="Yamamoto N" first="Noriyuki" last="Yamamoto">Noriyuki Yamamoto</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Izumi, Yasuhiko" sort="Izumi, Yasuhiko" uniqKey="Izumi Y" first="Yasuhiko" last="Izumi">Yasuhiko Izumi</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Matsuo, Takaaki" sort="Matsuo, Takaaki" uniqKey="Matsuo T" first="Takaaki" last="Matsuo">Takaaki Matsuo</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Wakita, Seiko" sort="Wakita, Seiko" uniqKey="Wakita S" first="Seiko" last="Wakita">Seiko Wakita</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Kume, Toshiaki" sort="Kume, Toshiaki" uniqKey="Kume T" first="Toshiaki" last="Kume">Toshiaki Kume</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Takada Akatori, Yuki" sort="Takada Akatori, Yuki" uniqKey="Takada Akatori Y" first="Yuki" last="Takada-Takatori">Yuki Takada-Takatori</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Faculty of Pharmaceutical Sciences, Doshisha Women's College, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Sawada, Hideyuki" sort="Sawada, Hideyuki" uniqKey="Sawada H" first="Hideyuki" last="Sawada">Hideyuki Sawada</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology and Clinical Research Center, Center for Neurological Diseases, Utano National Hospital, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07">2010-07</date><biblScope unit="volume">88</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1934">1934</biblScope><biblScope unit="page" to="1942">1942</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">838363552C12D01E9EC63C11DAEDE8EB5364C25F</idno><idno type="DOI">10.1002/jnr.22363</idno><idno type="ArticleID">JNR22363</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>heme oxygenase‐1</term><term>neuroprotection</term><term>proteasome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Postmortem studies have shown that heme oxygenase‐1 (HO‐1) immunoreactivity is increased in patients with Parkinson disease. HO‐1 expression is highly upregulated by a variety of stress. Since the proteasome activity is decreased in patients with Parkinson disease, we investigated whether proteasome activity regulates HO‐1 content. MG‐132, a proteasome inhibitor, increased the amount of HO‐1 protein mainly in astrocytes of primary mesencephalic cultures. Quantitative RT‐PCR analysis revealed that lactacystin upregulated HO‐1 mRNA expression. Proteasome inhibition with MG132 also increased the cytomegalovirus promoter‐driven expression of Flag‐HO‐1 protein and resulted in an accumulation of ubiquitinated Flag‐HO‐1 in Flag‐HO‐1‐overexpressing PC12 cells. In addition, a cycloheximide chase assay demonstrated that the degradation of Flag‐HO‐1 protein was slowed by MG‐132. Next, the function of HO‐1 which was upregulated by proteasome inhibitors was examined. Proteasome inhibitors protected dopaminergic neurons from 6‐hydroxydopamine (6‐OHDA)‐induced toxicity and this neuroprotection was abrogated by co‐treatment with zinc protoporphyrin IX, a HO‐1 inhibitor. Furthermore, 6‐OHDA‐induced toxicity was blocked by bilirubin and carbon monoxide, products of the HO‐1‐catalyzed degradation of heme. These results suggest that mesencephalic HO‐1 protein level is regulated by proteasome activity and the elevation by proteasome inhibition affords neuroprotection. © 2010 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région du Kansai</li></region><settlement><li>Kyoto</li></settlement><orgName><li>Université de Kyoto</li></orgName></list><tree><country name="Japon"><region name="Région du Kansai"><name sortKey="Yamamoto, Noriyuki" sort="Yamamoto, Noriyuki" uniqKey="Yamamoto N" first="Noriyuki" last="Yamamoto">Noriyuki Yamamoto</name></region><name sortKey="Akaike, Akinori" sort="Akaike, Akinori" uniqKey="Akaike A" first="Akinori" last="Akaike">Akinori Akaike</name><name sortKey="Izumi, Yasuhiko" sort="Izumi, Yasuhiko" uniqKey="Izumi Y" first="Yasuhiko" last="Izumi">Yasuhiko Izumi</name><name sortKey="Kume, Toshiaki" sort="Kume, Toshiaki" uniqKey="Kume T" first="Toshiaki" last="Kume">Toshiaki Kume</name><name sortKey="Matsuo, Takaaki" sort="Matsuo, Takaaki" uniqKey="Matsuo T" first="Takaaki" last="Matsuo">Takaaki Matsuo</name><name sortKey="Sawada, Hideyuki" sort="Sawada, Hideyuki" uniqKey="Sawada H" first="Hideyuki" last="Sawada">Hideyuki Sawada</name><name sortKey="Takada Akatori, Yuki" sort="Takada Akatori, Yuki" uniqKey="Takada Akatori Y" first="Yuki" last="Takada-Takatori">Yuki Takada-Takatori</name><name sortKey="Wakita, Seiko" sort="Wakita, Seiko" uniqKey="Wakita S" first="Seiko" last="Wakita">Seiko Wakita</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000731 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000731 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:838363552C12D01E9EC63C11DAEDE8EB5364C25F
|texte= Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection
}}
| This area was generated with Dilib version V0.6.23. |  |